Description

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on engineering proteases as therapeutics for hemophilia, hemeostasis, complement-mediated diseases, and other unmet medical needs. Its product pipeline includes CB 813d, a Factor VIIa drug candidate that completed a Phase I clinical trials evaluating safety and tolerability, as well as pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with and without inhibitors. The company’s preclinical development stage drugs comprise CB 2679d/ISU 304, a next-generation Factor IX drug for the treatment of patients with hemophilia B; and a Factor Xa variant. It is also developing CB 2782, an anti-C3 inflammation development candidate for the treatment of delayed graft function in kidney transplants; and an ophthalmic anti-C3 candidate for treatment of dry age-related macular degeneration. The company has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials. Catalyst Biosciences, Inc. is headquartered in South San Francisco, California.